fatnews.com Home page  >  Article | Previous article | Next article

SEARCH

QUICKLINKS AND VIEW OPITONS

  • Categories of Articles
  • Summary View
  • Headline View
  • Archive of Quotes
  • Contact Us
  • Follow @fatnews

    Qsymia (phentermine / topiramate), possibility of Myopia (nearsightedness) and Glaucoma


    Posted by .(JavaScript must be enabled to view this email address)
    Thursday, July 19, 2012 11:19 am Email this article

    Here is information about the possibility of Myopia [nearsightedness] and glaucoma with the use of Qsymia (phentermine / topirimate) as shown in the prescribing information.

    Acute Myopia [nearsightedness] and Secondary Angle Closure Glaucoma

    A syndrome consisting of acute myopia [nearsightedness] associated with secondary angle closure glaucoma has been reported in patients treated with topiramate, a component of Qsymia. 

    Symptoms include acute onset of decreased visual acuity and/or ocular pain.

    Ophthalmologic findings can include myopia, anterior chamber shallowing, ocular hyperemia (redness), and increased intraocular pressure. 

    Mydriasis [prolonged abnormal dilatation of the pupil of the eye] may or may not be present. 

    This syndrome may be associated with supraciliary effusion resulting in anterior displacement of the lens and iris, with secondary angle closure glaucoma. 

    Symptoms typically occur within one month of initiating treatment with topiramate but may occur at any time during therapy. 

    The primary treatment to reverse symptoms is immediate discontinuation of Qsymia. 

    Elevated intraocular pressure of any etiology, if left untreated, can lead to serious adverse events including permanent loss of vision.

    Info about Qseymia

    Info about Qseymia from the FDA

    The following information is from the FDA’s press release.

    “The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).

    “BMI, which measures body fat based on an individual’s weight and height, is used to define the obesity and overweight categories.

    “According to the Centers for Disease Control and Prevention, more than one-third of adults in the United States are obese.

    “Obesity threatens the overall well being of patients and is a major public health concern,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research.

    “Qsymia, used responsibly in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, provides another treatment option for chronic weight management in Americans who are obese or are overweight and have at least one weight-related comorbid condition.”

    “Qsymia is a combination of two FDA-approved drugs, phentermine and topiramate, in an extended-release formulation.

    “Phentermine is indicated for short-term weight loss in overweight or obese adults who are exercising and eating a reduced calorie diet.

    “Topiramate is indicated to treat certain types of seizures in people who have epilepsy and to prevent migraine headaches.”

    Reference

    Qsymia full prescribing information. July 17, 2012.
    http://www.qsymia.com/pdf/full-prescribing-information.pdf

    More Info

    More info about Qsymia here

    Drug companies website:

    Other Articles

    Other articles about Qsymia (formerly Qnexa)

    Articles on the same subject can be found here:


    COMMENTS

    Please feel free to share your comments about this article.


    Name:

    Email:

    Comments:

    Please enter the word you see in the image below:


    Remember my personal information

    Notify me of follow-up comments?



    © Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.